Frequent methylation of p16INK4A/p14ARF promoters in tumorigenesis of Epstein-Barr virus transformed lymphoblastoid cell lines

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2153-2160

  Nagy, Etelka ^a   Veress, György ^a   Szarka, Krisztina ^a   Csoma, Eszter ^a   Beck, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Burkitt lymphoma; Genetic change; LCL; p14ARF; p16INK4A; Promoter methylation

Indexed keywords

PROTEIN P14ARF; PROTEIN P16INK4A;

ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL IMMORTALIZATION; CONTROLLED STUDY; DNA METHYLATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MISSENSE MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; CELL LINE; GENE DELETION; GENE SILENCING; GENETICS; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY; VIRUS CELL TRANSFORMATION;

B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE DELETION; GENE SILENCING; HERPESVIRUS 4, HUMAN; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 21344437277     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Young LS and Murray PG: Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121, 2003.
2. Nilsson K: Human B-lymphoid cell lines. Hum Cell 5: 25-41, 1992.
3. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H and Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743-2751, 1987.
4. Gregory CD, Rowe M and Rickinson AB: Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71(Pt 7): 1481-1495, 1990.
5. Touitou R, Arbach H, Cochet C, Feuillard J, Martin A, Raphael M and Joab I: Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type 1 Burkitt's lymphoma cell lines. J Gen Virol 84: 949-957, 2003.
6. Okubo M, Tsurukubo Y, Higaki T, Kawabe T, Goto M, Murase T, Ide T, Furuichi Y and Sugimoto M: Clonal chromosomal aberrations accompanied by strong telomerase activity in immortalization of human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Genet Cytogenet 129: 30-34, 2001.
7. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
8. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH and Peters G: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001-5014, 1998.
9. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P and Wiman KG: p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91: 1680-1687, 1998.
10. Ruas M and Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-F177, 1998.
11. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB and Herman JG: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133, 2000.
12. Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12: 845-859, 1998.
13. Krug U, Ganser A and Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21: 3475-3495, 2002.
14. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ and Baylin SB: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841, 1997.
15. Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT and Chaubert P: Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 94: 1773-1781, 1999.
16. Sanchez-Beato M, Saez AI, Navas IC, Algara P, Sol MM, Villuendas R, Camacho F, Sanchez-Aguilera A, Sanchez E and Piris MA: Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159: 205-213, 2001.
17. Lindstrom MS, Klangby U and Wiman KG: p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 20: 2171-2177, 2001.
18. Sugimoto M, Tahara H, Ide T and Furuichi Y: Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res 64: 3361-3364, 2004.
19. Rowe M, Rooney CM, Edwards CF, Lenoir GM and Rickinson AB: Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer 37: 367-373, 1986.
20. Klein G, Giovanella B, Westman A, Stehlin JS and Mumford D: An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5: 319-334, 1975.
21. Magrath IT, Pizzo PA, Whang-Peng J, Douglass EC, Alabaster O, Gerber P, Freeman CB and Novikovs L: Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. J Natl Cancer Inst 64: 465-476, 1980.
22. Takada K: Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 33: 27-32, 1984.
23. Klein G, Dombos L and Gothoskar B: Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer 10: 44-57, 1972.
24. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H and Clifford P: Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28: 1300-1310, 1968.
25. Hinuma Y, Konn M, Yamaguchi J, Wudarski DJ, Blakeslee JR, Jr and Grace JT Jr: Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol 1: 1045-1051, 1967.
26. Nadkarni JS, Nadkarni JJ, Clifford P, Manolov G, Fenyo EM and Klein E: Characteristics of new cell lines derived from Burkitt lymphomas. Cancer 23: 64-79, 1969.
27. Bodescot M, Chambraud B, Farrell P and Perricaudet M: Spliced RNA from the IR1-U2 region of Epstein-Barr virus: presence of an open reading frame for a repetitive polypeptide. EMBO J 3: 1913-1917, 1984.
28. Hedman H and Lundgren E: Regulation of LFA-1 avidity in human B cells. Requirements for dephosphorylation events for high avidity ICAM-1 binding. J Immunol 149: 2295-2299, 1992.
29. Ernberg I, Kallin B, Dillner J, Falk K, Ehlin-Henriksson B, Hammarskjold ML and Klein G: Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int J Cancer 38: 729-737, 1986.
30. Speck SH and Strominger JL: Analysis of the transcript encoding the latent Epstein-Barr virus nuclear antigen I: a potentially polycistronic message generated by long-range splicing of several exons. Proc Natl Acad Sci USA 82: 8305-8309, 1985.
31. Kavathas P, Bach FH and DeMars R: Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. Proc Natl Acad Sci USA 77: 4251-4255, 1980.
32. Sinclair AJ, Palmero I, Peters G and Farrell PJ: EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13: 3321-3328, 1994.
33. Nagy E, Beck Z, Kiss A, Csoma E, Telek B, Konya J, Olah E, Rak K and Toth FD: Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer 39: 2298-2305, 2003.
34. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
35. Lindstrom MS and Wiman KG: Role of genetic and epigenetic changes in Burkitt lymphoma. Sem Cancer Biol 12: 381-387, 2002.
36. Kataoka H, Tahara H, Watanabe T, Sugawara M, Ide T, Goto M, Furuichi Y and Sugimoto M: Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity. Differentiation 62: 203-211, 1997.
37. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
38. Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M and Piris MA: p 14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 99: 1411-1418, 2002.
39. Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A, Trias M and Wiencke JK: Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 21: 2057-2064, 2000.